Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $500,100.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO traded up $0.68 during trading hours on Tuesday, reaching $51.19. 1,779,578 shares of the company’s stock were exchanged, compared to its average volume of 1,469,034. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The firm has a market capitalization of $6.51 billion, a price-to-earnings ratio of 16.95, a P/E/G ratio of 0.44 and a beta of 1.24. The company has a 50-day moving average of $50.09 and a 200 day moving average of $54.01.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on HALO. HC Wainwright reaffirmed a “buy” rating and set a $68.00 target price on shares of Halozyme Therapeutics in a research note on Monday, December 30th. JMP Securities upped their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $58.00 to $62.00 in a report on Monday, October 7th. Piper Sandler upped their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Finally, Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $61.11.

Institutional Trading of Halozyme Therapeutics

Several hedge funds have recently made changes to their positions in the company. Commonwealth Equity Services LLC lifted its holdings in Halozyme Therapeutics by 34.3% in the second quarter. Commonwealth Equity Services LLC now owns 20,382 shares of the biopharmaceutical company’s stock valued at $1,067,000 after acquiring an additional 5,210 shares during the period. Natixis Advisors LLC boosted its holdings in Halozyme Therapeutics by 22.1% during the second quarter. Natixis Advisors LLC now owns 65,099 shares of the biopharmaceutical company’s stock worth $3,409,000 after buying an additional 11,763 shares in the last quarter. Private Advisor Group LLC grew its position in Halozyme Therapeutics by 1.8% during the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company’s stock worth $1,191,000 after buying an additional 412 shares during the period. LSV Asset Management increased its holdings in Halozyme Therapeutics by 32.9% in the second quarter. LSV Asset Management now owns 613,800 shares of the biopharmaceutical company’s stock valued at $32,139,000 after buying an additional 152,000 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at approximately $195,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.